Title: Secondary Conditions After SCI: Recognizing and Treating Cardiovascular Disease, Osteoporosis and Bl
1Secondary Conditions After SCI Recognizing and
Treating Cardiovascular Disease, Osteoporosis and
Bladder Cancer
- Suzanne L. Groah, MD, MSPH
- www.SCI-Health.Org
2Objectives
- List 3 major secondary conditions that occur
after SCI - Discuss risk factors for each of these secondary
conditions - Describe when and how to monitor for these
secondary conditions
3Part 1 Bladder Cancer Risk and Prevention
4Bladder Cancer Epidemiology
- 5th most common cancer
- 12th leading cause of cancer mortality
- Adjusted yearly incidence 17.0 per 100,000
- 54,400 new cases per year
- Males at greater risk
- Majority are transitional cell carcinoma
5Risk Factors for Bladder Cancer
- Smoking
- Male gender
- Aromatic amines
- Schistosomiasis
- UTI
6Hypotheses
- Incidence of bladder cancer is higher in SCI than
in the general population - Indwelling catheter use is associated with
bladder cancer in SCI - 3 There is an increasing risk of bladder cancer
with longer duration of IDC use
7Part 1 Design Retrospective Cohort
8Results
9Demographics
data presented in years
10Demographics
11Comparison to General Population (SMRMales)
12Risk of Bladder Cancer
- Age-adjusted rate of bladder cancer (per 100,000)
- Indwelling catheter - 77.0
- Multi methods- 56.1
- No indwelling catheter - 25.1
- Age-adjusted RR 4.9
- Attributable risk percent due to catheter 64.8
- Attributable risk percent due to SCI 55.8
13Factors Contributing to Bladder Cancer
14Cumulative Incidence of Bladder Cancer
Wilcoxan lt 0.05
15Cumulative Incidence of Bladder Cancer
Wilcoxan lt 0.05
16Part 1 Conclusions
- Incidence of bladder cancer is higher in SCI than
in the general population - Indwelling catheter use is associated with
bladder cancer in SCI - The risk of bladder cancer increases with
increasing duration of indwelling catheter use
17Part 2 Bladder Cancer Mortality
18Epidemiology of Bladder Cancer Mortality
- Adjusted risk 3.2 per 100,000
- Associated with age
- gt50 deaths occur in 70 year olds
- Mortality related to stage at diagnosis
- Superficial 5-yr survival 90
- Invasive 5-yr survival lt50
19Hypotheses
- Bladder cancer mortality is heightened in SCI
compared with the general population - 2 Compared with other bladder management methods,
indwelling catheter use is associated with
heightened BC mortality - 3 The risk of BC mortality increases with
increasing duration of indwelling catheter use
20Part 2 Design Retrospective Cohort
21Bladder Cancer Mortality
22Risks
- Indwelling catheter age-adjusted BC mortality
51.2/100,000 p-y - Multi age-adjusted BC mortality 31.5/100,000
p-y - SMR SCI vs. SEER 70.9
- SMR IDC vs. SEER 127.9
23Bladder Cancer Mortality by Age
24Proportional Mortality Due to Bladder Cancer
25Survival After Bladder Cancer Diagnosis
- Of those dying due to BC, majority of death
occurred in lt1 year - Survival range .4 3.3 years
26Part 2 Conclusions
- Bladder cancer mortality is heightened in SCI
compared with the general population - Compared with other bladder management methods,
IDC use is associated with heightened BC
mortality
27Part 3 Risk Factors, Diagnosis, and Surveillance
28Purpose
- To evaluate factors influencing survival after
bladder cancer in individuals with SCI - To examine bladder cancer surveillance
29Hypotheses
- Bladder cancer survivors have fewer genitourinary
risk factors than those dying due to bladder
cancer - 2 Bladder cancer survivors have undergone more
intense genitourinary surveillance
30Part 3 Design Case-control
31Methods
- Design case-control
- 8 BC survivors
- 12 BC controls who died
- Outcome measures
- Demographics
- Frequency of surveillance
- Risk factors
- Analyses
- Students t test
- Fishers exact test
32Demographics
33Demographics
data presented in years
34Presentation
35Diagnosis
36Bladder Cancer Histology
37Potential Associated Risk Factors
38Risk Factors
RF IDC use, tobacco use, calculi, or
pyelonephritis
39Hypothesis 2
- 2 Bladder cancer survivors have undergone more
intense genitourinary surveillance
40Bladder Cancer Surveillance
41Conclusions
- Bladder cancer survivors have fewer genitourinary
risk factors than those dying due to bladder
cancer - While IDC use is related to BC incidence,
concurrent multiple risk factor status may be
related to mortality - Bladder cancer survivors have undergone more
intense genitourinary surveillance
42Clinical Correlates
- Encourage methods of bladder management other
than indwelling catheters when appropriate - Foley and suprapubic catheters DO have a role
after SCI - In people at risk, encourage periodic screening
by a urologist
43Cardiovascular Disease
44Epidemiology of Cardiovascular Disease
- CVD is 1 cause of death in US
- 1993 CVD mortality rate 163 per 100,000
- 1993 CHD mortality rate 95 per 100,000
- 28.6 decline in mortality due to MI
- 84.6 of mortality due to MI in 65yo
45Reversible Risk Factors for CVD
- Hypertension
- Low HDL cholesterol
- Hypercholesterolemia
- Hypertriglyceridemia
- High lipoprotein A
- Tobacco use
- Sedentary lifestyle
- Abdominal obesity
- Diabetes mellitus
- Hyperinsulinemia
46Data from the Craig Collaborative Aging Study
47Cholesterol Level by Neurologic Group
48Serum Lipids
- Cholesterol significantly higher in ParaABCs and
All Ds than TetraABCs - HDL significantly lower in TetraABCs than All
Ds - HDL decreased significantly in ParaABCs and
TetraABCs over time
49CVD and CHD Mortality
- 33 total deaths
- CVD mortality rate 42
- CHD mortality rate 33
- CVD case fatality rate 22
- CHD case fatality rate 17
50Epidemiology of CHD and CVD
- General population
- CVD 1 COD
- CHD prevalence 12.7-22
- CHD accounts for 51.2 of CVD mortality
- 17 CVD mortality in lt65 yo
- Long-term SCI
- CVD 1 COD (30 yrs post-SCI)
- CHD prevalence 15
- CHD accounts for 79 of CVD mortality
- 64 CVD mortality in lt65 yo
- 35 deaths in those gt60 years
51Data from Cardiovascular Disease After Spinal
Cord Injury Suspected Causes, Available
Treatments, and Investigational Imperatives
52National Cholesterol Education Panel Guidelines
- HDL lt 40 is abnormal
- LDL 130 159 is borderline high
- LDL gt 160 is high
- LDL target is 100
- Triglyceride 150-199 is borderline high
- Triglyceride lt 150 is normal
53Observed Lipid Levels After Chronic Paraplegia
- Normal total cholesterol
- Normal or elevated LDL
- Normal or elevated triglycerides
- Consistently low HDL
- Significantly elevated TCHDL ratio
54Data from the University of Miami Risk
Stratification of Young, Healthy, Tobacco
Non-Users with Paraplegia at T6 and Lower Using
NCEP Guidelines
55Lipid Abnormalities
-
- ATP X s.d. Min Max Risk At Risk
- TC (mg/dl) II 172 34 97 225 lt 200 10/46
-
- III lt 200 10/46
- TG (mg/dl) II 189 45 100 300 lt 200 14/46
- III lt 150 32/46
- TC/HDL-C 4.2 1.1 2.4 6.5 lt 4.5 21/46
data from M. Nash, University of Miami, Miami
Project to Cure Paralysis
56Lipid Abnormalities
- ATP Mean s.d. Min / Max Risk At Risk
- HDL-C (mg/dl) II 44 12 23 / 68 gt 35
14/46 - III gt 40 25/46
- LDL-C (mg/dl) II 90 26 40 / 139 lt
130/160 16/46 1 - III lt 100/130 32/46 2
- ?2 (1) 70.453, p lt 0.001
- 1 ATP II Lipid-Lowering intervention indicated
in 16/46 (34.7) cases - 2 ATP III Lipid-Lowering intervention indicated
in 20/26 (69.6) cases
57Etiology of Lipid Abnormalities After Paraplegia
- Sedentary Lifestyle / Physical Deconditioning (L)
- Insulin Resistance / Metabolic Syndrome (X) (L,P)
- Imprudent Diet (P?)
58Clinical Correlates
- Role of nutrition and exercise
- Exercise may not be enough to correct the lipid
abnormalities associated with SCI - Monitor cholesterol and lipid levels
- Screen with exercise stress test
59Abnormal Calcium and Bone Metabolism After SCI
Osteoporosis, Stones and More
60Osteoporosis
- SCI results in immediate and often permanent
gravitational unloading - Similar to space flight
- Bone loss is universal after SCI
- Most persons with SCI will have a pathologic
fracture at some point - Osteoporosis occurs rapidly
61Bone Metabolism
- Normally there is a balance between
- Osteoclast (bone resorption/breakdown) activty
- Osteoblast (bone rebuilding) activity
- Pathology after SCI
- Imbalance between bone breakdown and bone
formation - After SCI osteoblastic AND osteoclastic activity
increase - Osteoblasts increase only slightly
- Osteoclast activity increases 10-fold, peaking at
10 weeks
62Etiology of Osteoporosis After SCI
- Gravitational unloading
- Lack of muscle traction on bone
- Acutely, absorption of Ca decreases after SCI
- Other neural factors
63Pathology of Abnormal Bone and Calcium Metabolism
- Increase in osteoclast activity within days/weeks
- ? urine calcium
- Observed within 10d, peaks 1-6m
- 2-4x that seen in people after prolonged bedrest
- ? blood calcium
- ? markers of bone resorption
64Osteoporosis
- Definition - Bone density less than 2.5 SD below
mean - Bone density loss
- Trabecular bone affected most
- Distal femur
- Proximal tibia
- Os calcis
- Bone loss greater with
- Paraplegics have gt arm BMD than tetraplegics
- Complete injury
65Bone Loss or Gain Post-SCI
66Osteoporosis
- Morbidity
- Pathologic fracture in 6
- Outpatient Model System Center review
- 14 at 5 years
- 28 at 10 years
- 39 at 15 years
- Sites
- Supracondylar region and tibia
- ? Fracture threshold of 50 loss for the knee
- Inciting event minimal/no trauma, ROM
67Osteoporosis
- Prevention
- Exercise
- Medications
- Restoration of bone loss difficult
- Monitor at risk individuals
68Osteoporosis/Abnormal Bone Metabolism
- Exercise
- Animal model Early mobilization of paralyzed
limbs with FES slowed bone loss - Acute (1-4 week) standing program slowed bone
loss at the tibia - Acute (1-5 weeks) standing/treadmill program in
incompletes halted bone loss - FES ambulation in completes with chronic SCI did
not restore BMD loss - FES cycling does not restore BMD chronically
69Osteoporosis/Abnormal Bone Metabolism
- Exercise
- FES to quads 1 hr/d, 5 d/wk x 24 weeks restores
LE bone loss (Belanger) - FES-cycle 30min/d, 3d/wk x 12 mos restores 10
proximal tibia bone loss (Mohr) - FES-cycle 30min/d, 1d/wk x 12 mos did not change
proximal tibia bone loss - RRTC Project R2 effect of FES 1hr/d, 5d/wk x 6
weeks acutely
70Osteoporosis/Abnormal Bone Metabolism
- Pharmacologic
- Bisphosphonates
- Etidronate shown to prevent BMD loss acutely,
but may inhibit formation - Pamidronate IV inhibited bone resorption and
reversed PTH inhibition - Alendronate increase BMD in ASIA D
- Zoledronate
71Clinical Correlates
- Osteoporosis is universal after SCI
- Osteoporosis likely can be prevented, but to what
degree and for how long? - Consider assessing BMD before initiating standing
or especially ambulation program - Consider assessment of BMD in those with chronic
SCI
72Thank you